PHARMACOVIGILANCE IN THE ERA OF COVID-19: A CONCISE REVIEW OF THE CURRENT SCENARIO, IMPLICATIONS, AND CHALLENGES

The pandemic of Coronavirus Disease 2019 (COVID-19) has now affected the entire globe which was first surfaced in China December 2019. In absence effective therapy to manage COVID-19, repurposed therapies were being used condition. view an urgent need for definitive therapy, multiple drugs, and investigational drug candidates are tried clinical trials may lead emergence unknown short term long adverse reactions (ADRs), hence it is crucial assess safety therapeutic interventions. lag pharmacovigilance activities midst this fosters under-reporting ADRs. Difficulty causality assessment due factors like wide variations presentation, concomitant use associated comorbidities, drug-drug drug-disease interaction forestalls appropriate assessment. Hydroxychloroquine, a antimalarial been part hue cry at present because its in-question patients with cardiac disorders. National International Drug monitoring centers have stressed upon reporting ADRs boost up process come various recommendations. We can overcome these issues by working cohesively, motivating HCPs report electronically, setting dedicated rapid response team tackle earliest.